Tag: SGLT-2

Hospitalization, ICU admission, and mortality among diabetic patients with inflammatory bowel disease receiving SGLT-2 inhibitors: a retrospective cohort study from the global collaborative network

aledopress

diabetes mellitus (T2DM) and inflammatory bowel disease (IBD) represent a high-risk population with competing comorbidities, complex medication regimens, and overlapping inflammatory pathways. Although the role of sodium-glucose co-transporter-2 (SGLT2) inhibitors in managing type 2 diabetes is well-established, their impact on outcomes in diabetic patients with coexisting IBD remains unclear. This study aimed to investigate the… Continue reading Hospitalization, ICU admission, and mortality among diabetic patients with inflammatory bowel disease receiving SGLT-2 inhibitors: a retrospective cohort study from the global collaborative network